High Priced Drugs

PhRMA has sued HHS and CMS over the GLOBE rule, arguing the agency has no authority to tie Medicare Part B drug payments to the prices paid in 19 other countries. The complaint leans on the major questions doctrine and a statutory ban on quality-adjusted life years. #SyenzaNews #MarketAccess #pharmaceuticals #healthcarepolicy #drugpricing

Lundbeck is trading scale for depth. Michala Fischer-Hansen, EVP for Europe and international markets, explains why 51 affiliates became 22, why a fifth of revenue now goes to R&D, and why US price pressure can decide where a medicine launches. #SyenzaNews #MarketAccess #brainhealth #pharma

US group health plans and issuers must rebuild their public price files under the Transparency in Coverage final rule: quarterly publication, an 11-claim threshold for out-of-network data, a new utilization file and attestation, and consumer phone disclosure from January 2027. #SyenzaNews #MarketAccess #PriceTransparency #HEOR

ADSE's October table cuts 119 maximum unit prices for hospital chemotherapy and drops prior authorisation from seven cancer medicines, including osimertinib. The workbook and the communiqué do not agree on the count. #SyenzaNews #MarketAccess #oncology

A National Press Foundation briefing on drug prices and workforce shortages: separate list price from net price, ask which goal a policy serves, and check whether more clinicians really mean more appointments. #SyenzaNews #HealthEconomics #MarketAccess

Germany drug pricing policies are now the subject of a US Section 301 investigation. AbbVie's chief counsel, Perry Siatis, has filed written evidence and testified that government price setting, mandatory rebates and reimbursement restrictions undercut the incentives that fund new medicines. He also cites a German-French working group on keeping innovative medicines available. #SyenzaNews #MarketAccess #DrugPricing #HEOR

Mounjaro passed €1 million in pharmacy sales in a single day in Portugal, on more than 3,000 packs, and the Ordem dos Médicos has asked Infarmed for prescription data. Here is what the numbers show on access, reimbursement and supply. #SyenzaNews #GLP1 #MarketAccess

South Africa has set a second single exit price adjustment for 2026, lifting listed medicine prices by 2.88% from 1 October. #SyenzaNews #MarketAccess #Pharma

Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma

The Fifth Circuit affirmed the constitutionality of the Medicare drug price negotiation program, rejecting claims from NICA, the Global Colon Cancer Association, and PhRMA. #SyenzaNews #DrugPricing #MarketAccess #Pharma

South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.